25 XP   0   0   10

Anavex Life Sciences Corp
Buy, Hold or Sell?

Let's analyse Anavex together

PenkeI guess you are interested in Anavex Life Sciences Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Anavex Life Sciences Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Anavex Life Sciences Corp

I send you an email if I find something interesting about Anavex Life Sciences Corp.

Quick analysis of Anavex (30 sec.)










What can you expect buying and holding a share of Anavex? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.65
Expected worth in 1 year
$1.66
How sure are you?
52.5%

+ What do you gain per year?

Total Gains per Share
$0.01
Return On Investment
0.2%

For what price can you sell your share?

Current Price per Share
$3.41
Expected price per share
$0 - $5.5076
How sure are you?
50%

1. Valuation of Anavex (5 min.)




Live pricePrice per Share (EOD)

$3.41

Intrinsic Value Per Share

$-3.67 - $-1.37

Total Value Per Share

$-2.02 - $0.28

2. Growth of Anavex (5 min.)




Is Anavex growing?

Current yearPrevious yearGrowGrow %
How rich?$135.5m$145.1m-$2.8m-2.0%

How much money is Anavex making?

Current yearPrevious yearGrowGrow %
Making money-$10.7m-$12.5m$1.7m16.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Anavex (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#326 / 1010

Most Revenue
#878 / 1010

Most Profit
#580 / 1010

Most Efficient
#321 / 1010

What can you expect buying and holding a share of Anavex? (5 min.)

Welcome investor! Anavex's management wants to use your money to grow the business. In return you get a share of Anavex.

What can you expect buying and holding a share of Anavex?

First you should know what it really means to hold a share of Anavex. And how you can make/lose money.

Speculation

The Price per Share of Anavex is $3.41. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anavex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anavex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.65. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anavex.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.11-3.1%-0.13-3.9%-0.15-4.5%-0.11-3.3%-0.08-2.4%
Usd Book Value Change Per Share-0.08-2.2%0.000.0%-0.03-1.0%0.072.1%0.041.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.08-2.2%0.000.0%-0.03-1.0%0.072.1%0.041.2%
Usd Price Per Share9.31-8.14-10.48-8.89-5.83-
Price to Earnings Ratio-22.17--15.91--17.58--18.97--19.16-
Price-to-Total Gains Ratio-121.79-64.64--148.14--219.55--106.81-
Price to Book Ratio5.64-4.71-5.92-9.73-16.12-
Price-to-Total Gains Ratio-121.79-64.64--148.14--219.55--106.81-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.41
Number of shares293
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.07
Usd Total Gains Per Share0.000.07
Gains per Quarter (293 shares)0.4021.12
Gains per Year (293 shares)1.6184.46
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102-808474
203-60169158
305-40253242
406-20338326
50800422410
601020507494
701140591578
801360676662
901480760746
10016100845830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.073.00.01.4%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%10.010.00.050.0%21.019.00.052.5%29.043.02.039.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.074.00.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%10.010.00.050.0%21.019.00.052.5%29.043.02.039.2%

Fundamentals of Anavex

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-04-11 01:37:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Anavex Life Sciences Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Anavex earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Anavex Life Sciences Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y--449.1%+449.1%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient Anavex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • -5.8% Return on Assets means that Anavex generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Anavex Life Sciences Corp:

  • The MRQ is -5.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.8%TTM-6.9%+1.1%
TTM-6.9%YOY-8.1%+1.1%
TTM-6.9%5Y-13.7%+6.7%
5Y-13.7%10Y-21.1%+7.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.8%-13.3%+7.5%
TTM-6.9%-12.8%+5.9%
YOY-8.1%-11.7%+3.6%
5Y-13.7%-13.9%+0.2%
10Y-21.1%-15.7%-5.4%
1.1.3. Return on Equity

Shows how efficient Anavex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • -6.4% Return on Equity means Anavex generated $-0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Anavex Life Sciences Corp:

  • The MRQ is -6.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.4%TTM-7.6%+1.2%
TTM-7.6%YOY-8.7%+1.1%
TTM-7.6%5Y-16.6%+9.1%
5Y-16.6%10Y-151.7%+135.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.4%-16.9%+10.5%
TTM-7.6%-16.1%+8.5%
YOY-8.7%-15.1%+6.4%
5Y-16.6%-19.3%+2.7%
10Y-151.7%-20.2%-131.5%

1.2. Operating Efficiency of Anavex Life Sciences Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Anavex is operating .

  • Measures how much profit Anavex makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Anavex Life Sciences Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y--492.1%+492.1%
10Y--632.4%+632.4%
1.2.2. Operating Ratio

Measures how efficient Anavex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y-5.739-5.739
10Y-7.876-7.876

1.3. Liquidity of Anavex Life Sciences Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Anavex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.85 means the company has $11.85 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 11.850. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.449. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.850TTM12.449-0.599
TTM12.449YOY15.725-3.277
TTM12.4495Y10.567+1.882
5Y10.56710Y8.727+1.840
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.8503.890+7.960
TTM12.4494.173+8.276
YOY15.7255.344+10.381
5Y10.5676.126+4.441
10Y8.7276.448+2.279
1.3.2. Quick Ratio

Measures if Anavex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • A Quick Ratio of 11.79 means the company can pay off $11.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 11.790. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.385. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.790TTM12.385-0.595
TTM12.385YOY15.678-3.293
TTM12.3855Y10.505+1.879
5Y10.50510Y8.656+1.849
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.7903.514+8.276
TTM12.3853.998+8.387
YOY15.6785.380+10.298
5Y10.5056.105+4.400
10Y8.6566.404+2.252

1.4. Solvency of Anavex Life Sciences Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Anavex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anavex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Anavex assets are financed with 8.4% credit (debt) and the remaining percentage (100% - 8.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 0.084. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.081. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.084TTM0.081+0.003
TTM0.081YOY0.066+0.014
TTM0.0815Y0.127-0.046
5Y0.12710Y0.186-0.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0840.339-0.255
TTM0.0810.336-0.255
YOY0.0660.271-0.205
5Y0.1270.366-0.239
10Y0.1860.389-0.203
1.4.2. Debt to Equity Ratio

Measures if Anavex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.2% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 0.092. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.088. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.092TTM0.088+0.004
TTM0.088YOY0.071+0.017
TTM0.0885Y0.154-0.065
5Y0.15410Y1.447-1.294
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0920.388-0.296
TTM0.0880.402-0.314
YOY0.0710.335-0.264
5Y0.1540.426-0.272
10Y1.4470.461+0.986

2. Market Valuation of Anavex Life Sciences Corp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Anavex generates.

  • Above 15 is considered overpriced but always compare Anavex to the Biotechnology industry mean.
  • A PE ratio of -22.17 means the investor is paying $-22.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Anavex Life Sciences Corp:

  • The EOD is -8.119. Based on the earnings, the company is expensive. -2
  • The MRQ is -22.166. Based on the earnings, the company is expensive. -2
  • The TTM is -15.909. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.119MRQ-22.166+14.047
MRQ-22.166TTM-15.909-6.257
TTM-15.909YOY-17.576+1.667
TTM-15.9095Y-18.965+3.056
5Y-18.96510Y-19.161+0.196
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.119-2.264-5.855
MRQ-22.166-2.629-19.537
TTM-15.909-2.680-13.229
YOY-17.576-4.145-13.431
5Y-18.965-6.257-12.708
10Y-19.161-6.254-12.907
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Anavex Life Sciences Corp:

  • The EOD is -9.566. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -26.116. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -22.909. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.566MRQ-26.116+16.550
MRQ-26.116TTM-22.909-3.207
TTM-22.909YOY-35.135+12.226
TTM-22.9095Y-30.552+7.643
5Y-30.55210Y-30.702+0.150
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.566-2.973-6.593
MRQ-26.116-3.333-22.783
TTM-22.909-3.553-19.356
YOY-35.135-5.605-29.530
5Y-30.552-8.376-22.176
10Y-30.702-8.865-21.837
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Anavex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.64 means the investor is paying $5.64 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Anavex Life Sciences Corp:

  • The EOD is 2.065. Based on the equity, the company is underpriced. +1
  • The MRQ is 5.639. Based on the equity, the company is overpriced. -1
  • The TTM is 4.707. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.065MRQ5.639-3.573
MRQ5.639TTM4.707+0.932
TTM4.707YOY5.917-1.210
TTM4.7075Y9.728-5.022
5Y9.72810Y16.121-6.393
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0651.896+0.169
MRQ5.6392.115+3.524
TTM4.7072.093+2.614
YOY5.9172.884+3.033
5Y9.7283.542+6.186
10Y16.1213.916+12.205
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Anavex Life Sciences Corp.

3.1. Institutions holding Anavex Life Sciences Corp

Institutions are holding 32.065% of the shares of Anavex Life Sciences Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc8.12430.0016667107560988410.0621
2023-12-31Vanguard Group Inc5.31060.000943606481153042.716
2023-12-31State Street Corporation4.43620.00173642702172530.4759
2023-12-31Geode Capital Management, LLC2.02810.00161665364923965.874
2023-12-31Nwam, LLC0.97220.5977982937730310.7218
2023-12-31Northern Trust Corp0.90290.0013741425-9942-1.3232
2023-12-31Susquehanna International Group, LLP0.87850.001372135327544061.7699
2023-12-31Charles Schwab Investment Management Inc0.75790.0015622310174992.8933
2023-09-30Citadel Advisors Llc0.70040.00085751075314491217.3004
2023-12-31Goldman Sachs Group Inc0.64930.0005533146312129141.224
2023-12-31Morgan Stanley - Brokerage Accounts0.55070.000445220317996066.1027
2023-12-31SG Americas Securities, LLC0.37460.02673075683815514.1623
2023-12-31Bank of New York Mellon Corp0.31190.0005256098-1602-0.6217
2023-12-31Nuveen Asset Management, LLC0.29280.0007240441138196.0978
2023-12-31Rafferty Asset Management, LLC0.28260.0091232031-38757-14.3127
2023-12-31Barclays PLC0.25630.00072104304985331.0462
2023-12-31UBS Group AG0.250.0006205285103904102.4886
2023-12-31Bank of America Corp0.24960.000220493883524.2485
2023-12-31Swiss National Bank0.19670.0011161500-16200-9.1165
2023-12-31State Of Wisconsin Investment Board0.16660.003613683469878104.3641
Total 27.69220.651822738751+2446077+10.8%

3.2. Funds holding Anavex Life Sciences Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF6.79760.37635581641704001.2774
2024-02-29Vanguard Total Stock Mkt Idx Inv2.76070.0008226687200
2024-03-28iShares Russell 2000 ETF2.14770.013717635348490.0482
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.46510.00611203062-1795-0.149
2024-01-31Fidelity Small Cap Index0.89290.0177733220114671.5888
2024-03-31Direxion Daily S&P Biotech Bull 3X ETF0.81590.2731669945-4700-0.6967
2024-03-28iShares Russell 2000 Growth ETF0.77610.0278637307-741-0.1161
2024-03-28iShares Biotechnology ETF0.73610.040360447100
2024-02-29Fidelity Extended Market Index0.59830.0066491320329397.1859
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.53450.005443889991002.1173
2024-03-29Schwab US Small-Cap ETF™0.47160.011538722400
2024-02-29Vanguard Health Care ETF0.33930.006927863514240.5137
2024-02-29Vanguard Russell 2000 ETF0.32070.0142263324206488.5085
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.31010.013325459600
2023-12-31NT R2000 Growth Index Fund - NL0.25950.053621311323691.1241
2023-12-31NT R2000 Index Fund - NL0.24890.026220439826191.298
2023-09-30BlackRock Extended Mkt Composite0.23480.00919280612610.6583
2024-03-31BlackRock Extended Equity Market K0.22730.006518664745102.4762
2024-02-29Schwab Small Cap Index0.20210.014416597400
2023-12-31NT R2000 Growth Index Fund - L0.19780.0545162450108897.1846
Total 20.3370.977916699438+161239+1.0%

3.3. Insider Transactions

Insiders are holding 3.144% of the shares of Anavex Life Sciences Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-28Christopher U MisslingSELL733805.11
2023-06-28Christopher U MisslingSELL2680007.98

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Anavex Life Sciences Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0760.001-5668%-0.034-55%0.072-206%0.042-283%
Book Value Per Share--1.6511.733-5%1.768-7%1.145+44%0.656+152%
Current Ratio--11.85012.449-5%15.725-25%10.567+12%8.727+36%
Debt To Asset Ratio--0.0840.081+4%0.066+27%0.127-33%0.186-55%
Debt To Equity Ratio--0.0920.088+5%0.071+29%0.154-40%1.447-94%
Dividend Per Share----0%-0%-0%-0%
Eps---0.105-0.131+25%-0.152+45%-0.114+8%-0.080-24%
Free Cash Flow Per Share---0.089-0.089+0%-0.081-9%-0.076-14%-0.051-43%
Free Cash Flow To Equity Per Share---0.0880.000-20403%-0.023-74%0.075-218%0.042-313%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.374--------
Intrinsic Value_10Y_min---3.671--------
Intrinsic Value_1Y_max---0.194--------
Intrinsic Value_1Y_min---0.340--------
Intrinsic Value_3Y_max---0.540--------
Intrinsic Value_3Y_min---1.053--------
Intrinsic Value_5Y_max---0.834--------
Intrinsic Value_5Y_min---1.792--------
Market Cap280003611.360-173%764467337.760668395717.440+14%860128395.600-11%729774808.200+5%478818492.300+60%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio2.065-173%5.6394.707+20%5.917-5%9.728-42%16.121-65%
Pe Ratio-8.119+63%-22.166-15.909-28%-17.576-21%-18.965-14%-19.161-14%
Price Per Share3.410-173%9.3108.140+14%10.475-11%8.888+5%5.831+60%
Price To Free Cash Flow Ratio-9.566+63%-26.116-22.909-12%-35.135+35%-30.552+17%-30.702+18%
Price To Total Gains Ratio-44.608+63%-121.78964.642-288%-148.140+22%-219.551+80%-106.809-12%
Quick Ratio--11.79012.385-5%15.678-25%10.505+12%8.656+36%
Return On Assets---0.058-0.069+19%-0.081+39%-0.137+135%-0.211+262%
Return On Equity---0.064-0.076+19%-0.087+36%-0.166+162%-1.517+2285%
Total Gains Per Share---0.0760.001-5668%-0.034-55%0.072-206%0.042-283%
Usd Book Value--135575000.000142336662.500-5%145139189.750-7%94055804.150+44%53874527.900+152%
Usd Book Value Change Per Share---0.0760.001-5668%-0.034-55%0.072-206%0.042-283%
Usd Book Value Per Share--1.6511.733-5%1.768-7%1.145+44%0.656+152%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.105-0.131+25%-0.152+45%-0.114+8%-0.080-24%
Usd Free Cash Flow---7318000.000-7327185.750+0%-6632791.500-9%-6268926.600-14%-4170681.100-43%
Usd Free Cash Flow Per Share---0.089-0.089+0%-0.081-9%-0.076-14%-0.051-43%
Usd Free Cash Flow To Equity Per Share---0.0880.000-20403%-0.023-74%0.075-218%0.042-313%
Usd Market Cap280003611.360-173%764467337.760668395717.440+14%860128395.600-11%729774808.200+5%478818492.300+60%
Usd Price Per Share3.410-173%9.3108.140+14%10.475-11%8.888+5%5.831+60%
Usd Profit---8622000.000-10788820.500+25%-12516817.500+45%-9362779.450+9%-6601865.850-23%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.0760.001-5668%-0.034-55%0.072-206%0.042-283%
 EOD+3 -5MRQTTM+13 -16YOY+9 -205Y+18 -1110Y+14 -15

4.2. Fundamental Score

Let's check the fundamental score of Anavex Life Sciences Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.119
Price to Book Ratio (EOD)Between0-12.065
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than111.790
Current Ratio (MRQ)Greater than111.850
Debt to Asset Ratio (MRQ)Less than10.084
Debt to Equity Ratio (MRQ)Less than10.092
Return on Equity (MRQ)Greater than0.15-0.064
Return on Assets (MRQ)Greater than0.05-0.058
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Anavex Life Sciences Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.065
Ma 20Greater thanMa 504.291
Ma 50Greater thanMa 1004.817
Ma 100Greater thanMa 2005.994
OpenGreater thanClose3.710
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets148,070
Total Liabilities12,495
Total Stockholder Equity135,575
 As reported
Total Liabilities 12,495
Total Stockholder Equity+ 135,575
Total Assets = 148,070

Assets

Total Assets148,070
Total Current Assets148,070
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 143,765
Net Receivables 3,549
Other Current Assets 756
Total Current Assets  (as reported)148,070
Total Current Assets  (calculated)148,070
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,495
Long-term Liabilities7,286
Total Stockholder Equity135,575
Total Current Liabilities
Accounts payable 4,292
Other Current Liabilities 7,286
Total Current Liabilities  (as reported)12,495
Total Current Liabilities  (calculated)11,578
+/- 917
Long-term Liabilities
Long-term Liabilities  (as reported)7,286
Long-term Liabilities  (calculated)0
+/- 7,286
Total Stockholder Equity
Common Stock82
Retained Earnings -301,691
Other Stockholders Equity 437,184
Total Stockholder Equity (as reported)135,575
Total Stockholder Equity (calculated)135,575
+/-0
Other
Capital Stock82
Cash and Short Term Investments 143,765
Common Stock Shares Outstanding 82,078
Current Deferred Revenue917
Liabilities and Stockholders Equity 148,070
Net Debt -143,765
Net Invested Capital 135,575
Net Working Capital 135,575



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-31
> Total Assets 
0
0
0
1
0
0
20
12
5
15
0
0
0
93
112
7
7
79
799
409
73
229
1,572
330
489
65
1,279
203
85
191
22
13
80
0
3
393
151
10,293
9,314
7,354
7,050
6,364
8,043
15,470
14,024
12,115
9,844
9,499
21,374
23,607
24,907
27,838
28,344
25,896
26,795
24,376
22,096
20,550
21,968
25,329
31,424
31,021
31,630
34,542
54,334
83,574
166,420
161,616
156,896
160,276
160,221
152,705
148,372
159,186
157,810
154,386
148,070
148,070154,386157,810159,186148,372152,705160,221160,276156,896161,616166,42083,57454,33434,54231,63031,02131,42425,32921,96820,55022,09624,37626,79525,89628,34427,83824,90723,60721,3749,4999,84412,11514,02415,4708,0436,3647,0507,3549,31410,29315139330801322191852031,279654893301,572229734097997977112930001551220001000
   > Total Current Assets 
0
0
0
1
0
0
20
12
5
15
0
0
0
14
11
6
6
79
743
407
71
228
1,537
326
486
62
1,276
201
83
190
21
13
80
0
3
393
149
9,222
8,199
7,351
7,049
6,363
8,041
15,469
14,023
12,114
9,843
9,446
21,322
23,554
24,854
27,786
28,291
25,812
26,742
24,324
22,096
20,550
21,817
25,329
31,424
31,021
31,630
34,542
54,334
83,574
166,420
161,616
156,896
160,276
160,221
152,705
148,372
159,186
157,810
154,386
148,070
148,070154,386157,810159,186148,372152,705160,221160,276156,896161,616166,42083,57454,33434,54231,63031,02131,42425,32921,81720,55022,09624,32426,74225,81228,29127,78624,85423,55421,3229,4469,84312,11414,02315,4698,0416,3637,0497,3518,1999,22214939330801321190832011,276624863261,53722871407743796611140001551220001000
       Cash And Cash Equivalents 
0
0
0
1
0
0
20
12
5
15
0
0
0
9
6
6
6
79
743
351
21
145
1,458
265
424
4
1,223
135
9
179
18
11
80
0
2
345
96
9,194
8,180
7,262
6,981
6,311
8,025
15,291
13,853
11,951
9,727
9,187
21,161
23,352
24,793
27,440
28,049
25,657
25,828
22,931
20,715
19,458
21,249
22,186
27,458
26,563
27,619
29,249
47,358
75,859
157,560
152,108
151,146
153,343
153,199
149,158
143,622
153,467
154,817
151,024
143,765
143,765151,024154,817153,467143,622149,158153,199153,343151,146152,108157,56075,85947,35829,24927,61926,56327,45822,18621,24919,45820,71522,93125,82825,65728,04927,44024,79323,35221,1619,1879,72711,95113,85315,2918,0256,3116,9817,2628,1809,194963452080111817991351,22344242651,458145213517437966690001551220001000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
43
15
15
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000015154300000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38
38
9
21
1
3
1
0
0
0
0
0
0
0
0
0
77
0
0
0
77
92
79
48
79
49
61
8
10
7
5
6
40
30
76
93
2,643
3,731
4,152
3,548
4,849
6,578
7,328
8,601
9,137
5,372
6,469
6,560
3,193
4,094
4,738
2,165
2,709
3,549
3,5492,7092,1654,7384,0943,1936,5606,4695,3729,1378,6017,3286,5784,8493,5484,1523,7312,643937630406571086149794879927700077000000000131219383800000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
10
5
5
0
0
0
0
56
50
83
79
23
62
49
32
65
70
10
3
1
0
0
2
48
53
28
19
89
68
52
16
101
77
85
68
180
111
142
53
336
235
151
909
1,353
1,350
1,016
475
501
235
306
463
444
399
387
258
372
378
465
462
354
656
982
828
653
756
7566538289826563544624653783722583873994444633062355014751,0161,3501,35390915123533653142111180688577101165268891928534820013107065324962237983505600005510000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
72
79
101
0
1
1
56
2
2
1
34
4
4
3
3
2
2
2
1
1
0
0
0
0
2
1,070
1,115
2
2
2
2
1
1
1
1
52
52
52
52
52
52
83
52
52
52
0
151
0
0
0
0
5,293
0
0
0
9,509
0
0
0
3,546,742
0
0
0
3,362
0
03,3620003,546,7420009,5090005,2930000151052525283525252525252111122221,1151,0702000011222334434122561101017972000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
2
2
1
1
4
4
3
3
2
2
2
1
1
0
0
0
0
2
2
2
2
2
2
2
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000011112222222000011222334411221111110000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
72
78
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000001007872000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
72
78
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000001007872000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,069
1,113
0
0
0
0
0
0
0
0
53
52
53
53
52
53
83
52
52
1,381
1,092
151
0
3,966
4,458
0
-5,293
6,977
7,715
0
-9,509
5,750
6,934
7,022
-3,546,742
4,750
5,719,435
2,992,699
-3,362
4,305
4,305-3,3622,992,6995,719,4354,750-3,546,7427,0226,9345,750-9,50907,7156,977-5,29304,4583,96601511,0921,381525283535253535253000000001,1131,0690000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
151
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001510000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
27
33
38
30
28
32
212
452
463
463
1,108
1,791
2,299
2,299
3,273
3,504
4,266
4,555
5,848
8,847
3,290
583
1,294
2,253
1,345
2,566
3,119
2,220
2,888
3,409
3,435
3,557
2,857
1,821
1,884
1,905
7,161
6,577
1,662
1,018
2,661
2,533
2,432
2,173
3,191
2,195
2,120
1,455
3,584
2,798
3,417
3,209
3,885
4,876
6,371
4,337
5,040
5,464
6,229
6,949
7,306
8,033
7,764
9,274
10,798
10,529
8,071
9,485
10,214
13,248
14,021
11,055
12,534
12,495
12,49512,53411,05514,02113,24810,2149,4858,07110,52910,7989,2747,7648,0337,3066,9496,2295,4645,0404,3376,3714,8763,8853,2093,4172,7983,5841,4552,1202,1953,1912,1732,4322,5332,6611,0181,6626,5777,1611,9051,8841,8212,8573,5573,4353,4092,8882,2203,1192,5661,3452,2531,2945833,2908,8475,8484,5554,2663,5043,2732,2992,2991,7911,108463463452212322830383327000
   > Total Current Liabilities 
0
0
0
27
33
38
30
28
32
212
452
463
463
1,108
1,791
2,299
2,299
3,273
3,504
4,098
4,431
4,692
7,883
3,290
583
1,294
2,253
1,345
2,566
3,119
2,220
2,888
3,409
3,435
3,557
1,953
1,821
1,883
1,904
1,441
1,418
1,528
1,001
2,661
2,532
2,432
2,173
3,191
2,195
2,120
1,455
3,584
2,798
3,417
3,209
3,885
4,876
6,371
4,337
5,040
5,464
6,229
6,949
7,306
8,033
7,764
9,274
10,798
10,529
8,071
9,485
10,214
13,248
14,021
11,055
12,534
12,495
12,49512,53411,05514,02113,24810,2149,4858,07110,52910,7989,2747,7648,0337,3066,9496,2295,4645,0404,3376,3714,8763,8853,2093,4172,7983,5841,4552,1202,1953,1912,1732,4322,5322,6611,0011,5281,4181,4411,9041,8831,8211,9533,5573,4353,4092,8882,2203,1192,5661,3452,2531,2945833,2907,8834,6924,4314,0983,5043,2732,2992,2991,7911,108463463452212322830383327000
       Short-term Debt 
0
0
0
0
0
0
20
20
20
85
273
0
200
675
1,296
1,550
1,550
2,005
2,524
2,507
2,428
2,425
2,602
2,492
200
200
828
868
1,156
1,201
49
299
599
761
758
211
200
194
201
192
98
90
90
85
82
88
88
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88
0
0
0
0
0
0
0
0
0
0
0
0
000000000000880000000000000000088888285909098192201194200211758761599299491,2011,1568688282002002,4922,6022,4252,4282,5072,5242,0051,5501,5501,296675200027385202020000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
456
0
0
0
86
0
0
88
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000880086000456000000000000000000000000000000000000000
       Accounts payable 
0
0
0
17
24
10
10
8
12
127
179
0
463
433
495
0
749
1,268
0
1,592
0
0
0
0
383
1,094
1,367
410
1,397
0
0
0
2,810
2,674
2,799
1,742
1,621
1,690
1,703
1,249
1,320
1,438
1,259
2,504
2,417
2,338
2,058
3,120
2,163
2,034
1,435
3,584
2,798
3,417
3,209
3,885
4,876
6,371
4,337
3,523
3,127
3,650
3,980
3,989
4,217
3,658
4,177
4,740
4,635
2,632
3,127
3,825
5,288
6,282
4,153
4,322
4,292
4,2924,3224,1536,2825,2883,8253,1272,6324,6354,7404,1773,6584,2173,9893,9803,6503,1273,5234,3376,3714,8763,8853,2093,4172,7983,5841,4352,0342,1633,1202,0582,3382,4172,5041,2591,4381,3201,2491,7031,6901,6211,7422,7992,6742,8100001,3974101,3671,09438300001,59201,2687490495433463017912712810102417000
       Other Current Liabilities 
0
0
0
10
9
27
0
0
0
0
0
0
0
1,108
0
0
1,074
3,273
980
0
2,003
2,267
5,282
798
583
1,294
1,425
68
13
1,919
2,171
2,589
2,810
2,674
2,799
1,742
1,621
1,690
1,703
1,249
1,320
1,438
911
2,504
2,417
2,338
2,058
3,120
2,163
2,034
1,435
3,584
2,798
3,417
3,209
3,885
4,876
6,371
4,337
1,516
2,336
2,579
2,969
3,317
3,817
3,619
4,653
5,615
5,450
4,995
5,914
5,945
7,043
6,823
5,986
7,295
7,286
7,2867,2955,9866,8237,0435,9455,9144,9955,4505,6154,6533,6193,8173,3172,9692,5792,3361,5164,3376,3714,8763,8853,2093,4172,7983,5841,4352,0342,1633,1202,0582,3382,4172,5049111,4381,3201,2491,7031,6901,6211,7422,7992,6742,8102,5892,1711,91913681,4251,2945837985,2822,2672,00309803,2731,074001,108000000027910000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
168
124
1,155
963
0
0
0
0
0
0
0
0
0
0
0
0
904
904
1
1
5,720
5,159
134
17
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,516
2,336
2,579
0
3,317
3,817
3,619
0
5,615
5,079
3,076
5,914
4,269
7,043
6,822,838
5,985,658
7,295
7,286
7,2867,2955,985,6586,822,8387,0434,2695,9143,0765,0795,61503,6193,8173,31702,5792,3361,5160000000000000000171345,1595,720119049040000000000009631,1551241680000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000110000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
151
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001510000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
904
0
0
0
5,456
4,938
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000004,9385,45600090400000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
904
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31
0
0
0
0
151
0
0
0
0
0
0
0
0
444
0
0
0
444
0
0
0
0
0
00000444000444000000001510000310000000000000000090400000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-26
-33
-38
-10
-16
-28
-197
-452
0
-463
-1,015
-1,679
0
-2,292
-3,193
-2,705
-3,858
-4,483
-5,619
-7,275
-2,960
-94
-1,229
-973
-1,142
-2,481
-2,928
-2,198
-2,875
-3,329
-3,435
-3,553
-2,463
-1,670
8,408
7,409
193
473
4,702
7,024
12,809
11,491
9,683
7,671
6,308
19,179
21,487
23,452
24,254
25,545
22,479
23,586
20,492
17,220
14,179
17,632
20,290
25,960
24,792
24,681
27,237
46,301
75,810
157,146
150,818
146,368
152,205
150,737
142,491
135,124
145,165
146,755
141,852
135,575
135,575141,852146,755145,165135,124142,491150,737152,205146,368150,818157,14675,81046,30127,23724,68124,79225,96020,29017,63214,17917,22020,49223,58622,47925,54524,25423,45221,48719,1796,3087,6719,68311,49112,8097,0244,7024731937,4098,408-1,670-2,463-3,553-3,435-3,329-2,875-2,198-2,928-2,481-1,142-973-1,229-94-2,960-7,275-5,619-4,483-3,858-2,705-3,193-2,2920-1,679-1,015-4630-452-197-28-16-10-38-33-26000
   Common Stock
0
0
0
3
3
3
19
19
19
19
19
0
20
20
20
0
20
20
21
21
21
21
22
24
25
25
26
27
27
27
30
30
30
30
30
37
38
38
38
47
55
65
96
32
35
36
36
36
41
41
42
43
44
45
45
46
47
48
52
53
57
59
60
62
67
70
75
76
76
77
78
78
78
80
81
82
82
82828180787878777676757067626059575352484746454544434241413636363532966555473838383730303030302727272625252422212121212020020202001919191919333000
   Retained Earnings Total Equity00-282,923-271,643-258,536-245,564-231,273-218,906-208,468-197,586-185,868-175,688-167,532-159,677-153,712-147,225-139,989-133,397-131,348-124,273-116,265-108,932-103,139-100,290-95,538-91,479-86,324-82,714-81,165-78,018-71,507-69,267-67,236-63,281-59,325-55,085-53,360-52,573-42,874-41,865-40,846-41,205-38,216-38,065-37,9580000-29,203-27,78200000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
126
0
0
-1
-1
0
0
-2
-2
0
0
-3
-4
-4
-5
-5
-6
-6
-6
-6
0
0
-1
-1
-1
-1
-2
-2
-2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000-2-2-2-1-1-1-100-6-6-6-6-5-5-4-4-300-2-200-1-1001260000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,783
28,034
0
0
0
0
34,600
34,600
34,600
38,645
39,078
49,595
49,605
52,079
53,138
59,082
65,031
74,061
76,128
78,914
79,142
84,290
100,303
104,159
109,734
115,689
121,039
122,724
126,679
129,378
133,438
138,404
148,928
153,634
165,892
171,958
178,333
186,852
213,766
251,428
342,938
348,328
354,760
371,438
381,932
387,977
393,582
416,728
429,596
0
0
00429,596416,728393,582387,977381,932371,438354,760348,328342,938251,428213,766186,852178,333171,958165,892153,634148,928138,404133,438129,378126,679122,724121,039115,689109,734104,159100,30384,29079,14278,91476,12874,06165,03159,08253,13852,07949,60549,59539,07838,64534,60034,60034,600000028,03426,78300000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
77
79
79
97
97
97
97
97
0
1,230
2,276
3,292
0
4,625
6,019
7,846
8,684
8,763
9,341
11,808
18,914
23,664
24,949
26,783
28,037
28,873
29,333
34,604
34,605
34,605
34,605
34,638
38,710
39,139
50,236
50,245
52,720
53,779
59,724
65,810
76,060
78,695
78,914
79,142
84,290
100,303
104,159
109,734
115,689
121,039
122,724
126,679
129,378
133,438
138,404
148,928
153,634
165,892
171,958
178,333
186,852
213,766
251,428
342,938
348,328
354,760
371,034
381,932
387,977
393,582
416,728
429,596
434,839
437,184
437,184434,839429,596416,728393,582387,977381,932371,034354,760348,328342,938251,428213,766186,852178,333171,958165,892153,634148,928138,404133,438129,378126,679122,724121,039115,689109,734104,159100,30384,29079,14278,91478,69576,06065,81059,72453,77952,72050,24550,23639,13938,71034,63834,60534,60534,60534,60429,33328,87328,03726,78324,94923,66418,91411,8089,3418,7638,6847,8466,0194,62503,2922,2761,23009797979797797977000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-09-30)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-55,756
Operating Income-47,498-55,756
 
Operating Expense (+$)
Research Development43,717
Selling General Administrative12,039
Selling And Marketing Expenses0
Operating Expense55,75655,756
 
Net Interest Income (+$)
Interest Income6,519
Interest Expense-964
Other Finance Cost-0
Net Interest Income5,555
 
Pretax Income (+$)
Operating Income-47,498
Net Interest Income5,555
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-47,498-50,176
EBIT - interestExpense = -48,462
-47,498
-46,527
Interest Expense964
Earnings Before Interest and Taxes (EBIT)-47,498-46,534
Earnings Before Interest and Taxes (EBITDA)-47,498
 
After tax Income (+$)
Income Before Tax-47,498
Tax Provision-7
Net Income From Continuing Ops-47,505-47,505
Net Income-47,491
Net Income Applicable To Common Shares-47,505
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses55,756
Total Other Income/Expenses Net2,678-5,555
 

Technical Analysis of Anavex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anavex. The general trend of Anavex is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anavex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Anavex Life Sciences Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.48 < 5.29 < 5.5076.

The bearish price targets are: .

Tweet this
Anavex Life Sciences Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Anavex Life Sciences Corp. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Anavex Life Sciences Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Anavex Life Sciences Corp. The current macd is -0.3728819.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Anavex price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Anavex. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Anavex price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Anavex Life Sciences Corp Daily Moving Average Convergence/Divergence (MACD) ChartAnavex Life Sciences Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Anavex Life Sciences Corp. The current adx is 25.53.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Anavex shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Anavex Life Sciences Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Anavex Life Sciences Corp. The current sar is 4.0781284.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Anavex Life Sciences Corp Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Anavex Life Sciences Corp. The current rsi is 23.07. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Anavex Life Sciences Corp Daily Relative Strength Index (RSI) ChartAnavex Life Sciences Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Anavex Life Sciences Corp. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Anavex price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Anavex Life Sciences Corp Daily Stochastic Oscillator ChartAnavex Life Sciences Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Anavex Life Sciences Corp. The current cci is -151.04061594.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Anavex Life Sciences Corp Daily Commodity Channel Index (CCI) ChartAnavex Life Sciences Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Anavex Life Sciences Corp. The current cmo is -70.11975519.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Anavex Life Sciences Corp Daily Chande Momentum Oscillator (CMO) ChartAnavex Life Sciences Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Anavex Life Sciences Corp. The current willr is -98.2300885.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Anavex Life Sciences Corp Daily Williams %R ChartAnavex Life Sciences Corp Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Anavex Life Sciences Corp.

Anavex Life Sciences Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Anavex Life Sciences Corp. The current atr is 0.26195535.

Anavex Life Sciences Corp Daily Average True Range (ATR) ChartAnavex Life Sciences Corp Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Anavex Life Sciences Corp. The current obv is -36,149,348.

Anavex Life Sciences Corp Daily On-Balance Volume (OBV) ChartAnavex Life Sciences Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Anavex Life Sciences Corp. The current mfi is 11.72.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Anavex Life Sciences Corp Daily Money Flow Index (MFI) ChartAnavex Life Sciences Corp Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Anavex Life Sciences Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Anavex Life Sciences Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Anavex Life Sciences Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.065
Ma 20Greater thanMa 504.291
Ma 50Greater thanMa 1004.817
Ma 100Greater thanMa 2005.994
OpenGreater thanClose3.710
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Anavex with someone you think should read this too:
  • Are you bullish or bearish on Anavex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anavex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Anavex Life Sciences Corp

I send you an email if I find something interesting about Anavex Life Sciences Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Anavex Life Sciences Corp.

Receive notifications about Anavex Life Sciences Corp in your mailbox!